Form 4: Linde Exec Sells Shares Under Pre-Arranged 10b5-1 Plan
Insider Transaction Report
Linde PLC's Executive VP & Chief Legal Officer, Guillermo Bichara, sold 4,357 ordinary shares for $480.79 each as part of a pre-scheduled 10b5-1 trading plan.
Summary
- Guillermo Bichara, Executive VP & Chief Legal Officer of Linde PLC, sold 4,357 ordinary shares.
- The shares were sold at a price of $480.79 per share on March 10, 2026.
- The transaction was executed under a Rule 10b5-1 trading plan established on August 22, 2025.
- Following the sale, Mr. Bichara directly owns 22,137.769 ordinary shares and indirectly owns 2,944.983 shares in a 401(k) plan.
- Mr. Bichara also holds various derivative securities, including Restricted Stock Units and Stock Options, with future vesting and expiration dates.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. While an executive sale reduces direct ownership, the pre-planned nature under a 10b5-1 plan mitigates concerns about its implications for the company's immediate future.
Positives
- The sale was conducted under a pre-arranged 10b5-1 plan, indicating a planned liquidity event rather than a reaction to new negative information.
Negatives
- An executive selling shares reduces their direct equity stake in the company.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that executive sales under Rule 10b5-1 plans are common practice for managing personal finances and diversifying holdings, particularly for long-tenured executives. This type of transaction is generally viewed as less indicative of management's immediate outlook on the company's prospects compared to unscheduled sales.
Comparison to Industry Standards
- Executive sales under Rule 10b5-1 plans are a standard practice across industries for managing personal liquidity and diversifying wealth. For example, similar planned sales have been observed at peer companies like Air Products and Chemicals (APD) and Praxair (now part of Linde), where executives periodically sell vested shares to manage their portfolios without signaling a negative outlook on the company's future performance.
- The volume of shares sold by Mr. Bichara represents a relatively small portion of his total beneficial ownership, including derivatives, which aligns with typical diversification strategies rather than a significant divestment.
Stakeholder Impact
- Shareholders: The sale by an executive could be perceived negatively, but the 10b5-1 plan context generally lessens this impact, suggesting a routine financial management decision rather than a lack of confidence.
- Employees: No direct impact on employees is indicated.
Next Steps
- Vesting and payout of 1,570 Restricted Stock Units on or about March 7, 2027.
- Vesting and payout of 1,613 Restricted Stock Units on or about March 7, 2028.
- Vesting and payout of 1,830 Restricted Stock Units on or about March 9, 2029.
- Ongoing vesting of various stock options in annual installments through March 2027.
Key Dates
| Date | Description |
|---|---|
| 2021-03-09 | Start of three consecutive equal annual installments for stock options with a $173.13 exercise price, expiring March 9, 2030. |
| 2022-03-08 | Start of three consecutive equal annual installments for stock options with a $253.68 exercise price, expiring March 8, 2031. |
| 2023-03-07 | Start of three consecutive equal annual installments for stock options with a $270.99 exercise price, expiring March 7, 2032. |
| 2024-03-07 | Start of three consecutive equal annual installments for stock options with a $354.14 exercise price, expiring March 7, 2033. |
| 2025-03-07 | Start of three consecutive equal annual installments for stock options with a $465.29 exercise price, expiring March 7, 2034. |
| 2025-08-22 | Date the 10b5-1 trading plan was entered into. |
| 2026-03-07 | Start of three consecutive equal annual installments for stock options with a $468.77 exercise price, expiring March 7, 2035. |
| 2026-03-10 | Date of the reported transaction (sale of ordinary shares). |
| 2026-03-12 | Date the Form 4 was signed. |
| 2027-03-07 | Restricted Stock Units (1,570 units) vest in full and payout. |
| 2027-03-09 | Start of three consecutive equal annual installments for stock options with a $483.62 exercise price, expiring March 9, 2036. |
| 2028-03-07 | Restricted Stock Units (1,613 units) vest in full and payout. |
| 2029-03-09 | Restricted Stock Units (1,830 units) vest in full and payout. |
| 2030-03-09 | Expiration date for stock options with a $173.13 exercise price. |
| 2031-03-08 | Expiration date for stock options with a $253.68 exercise price. |
| 2032-03-07 | Expiration date for stock options with a $270.99 exercise price. |
| 2033-03-07 | Expiration date for stock options with a $354.14 exercise price. |
| 2034-03-07 | Expiration date for stock options with a $465.29 exercise price. |
| 2035-03-07 | Expiration date for stock options with a $468.77 exercise price. |
| 2036-03-09 | Expiration date for stock options with a $483.62 exercise price. |
Recommendation
holdThe executive's sale of shares was conducted under a pre-established 10b5-1 plan, which is a routine financial management practice and does not typically signal a change in the company's fundamental outlook. While a reduction in executive ownership is generally a minor negative, the planned nature of the transaction suggests it is not a reaction to new adverse information. Therefore, the filing itself does not provide a strong basis for a 'buy' or 'sell' recommendation, supporting a 'hold' stance based solely on this insider transaction.
Keywords
Linde PLC, LIN, Form 4, insider trading, executive stock sale, Guillermo Bichara, 10b5-1 plan, ordinary shares, restricted stock units, stock options
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.